Charles Schwab
ELEV

Charles Schwab’s Elevation Oncology ELEV Stock Holding History

Charles Schwab’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-181,694
Closed -$47.1K – 3515
2025
Q1 		$47.1K Buy
181,694
+57,513
+46% +$32.8K ﹤0.01% 3409
2024
Q4 		$69.9K Hold
124,181
– – ﹤0.01% 3422
2024
Q3 		$74.5K Sell
124,181
-10,365
-8% -$15.4K ﹤0.01% 3389
2024
Q2 		$363K Buy
+134,546
New +$507K ﹤0.01% 3315

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Charles Schwab's ELEV Position: Q2 2025 in Review

Charles Schwab sold out of Elevation Oncology (ELEV) in Q2 2025, closing a stake of 181,694 shares — an estimated $47.1K sold.

Charles Schwab first reported a position in ELEV in Q2 2024 and held it in 4 quarters. The position peaked at $363K in Q2 2024. 65 funds tracked by Wall St. Rank hold ELEV as of Q2 2025.

  • Charles Schwab reported no remaining Elevation Oncology position as of Q2 2025 after selling out during the quarter.
  • Charles Schwab sold 181,694 Elevation Oncology shares in Q2 2025, an estimated $47.1K.
  • Charles Schwab first reported a position in Elevation Oncology in Q2 2024 and held it in 4 quarters.
  • Charles Schwab's Elevation Oncology position peaked at $363K in Q2 2024.
  • 65 funds tracked by Wall St. Rank held Elevation Oncology as of Q2 2025.

Based on Charles Schwab's 13F filing for Q2 2025, filed 12 Aug 2025.